Skip to Content
Merck

B7777

Budesonide

≥99%, anti-inflammatory, powder

Synonym(s):

16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C25H34O6
CAS Number:
51333-22-3
Molecular Weight:
430.53
NACRES:
NA.77
PubChem Substance ID:
24278277
UNSPSC Code:
12352200
EC Number:
257-139-7
MDL number:
MFCD00083259
Assay:
≥99%
Form:
powder
Quality level:
200

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Budesonide, ≥99%

InChI

1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1

InChI key

VOVIALXJUBGFJZ-KWVAZRHASA-N

SMILES string

[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO

assay

≥99%

form

powder

originator

AstraZeneca

Quality Level

200

Gene Information

human ... IFNG(3458), IL5(3567), NR3C1(2908)
rat ... Nr3c1(24413)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice.
Second generation glucocorticoid with low systemic absorption; anti-inflammatory agent; inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein.

Features and Benefits

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - Skin Sens. 1 - STOT RE 1 Inhalation

target_organs

Adrenal gland

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

B7777-VAR: + B7777-250MG: + B7777-50MG: + B7777-BULK:

jan

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM4027
BCCH8271
BCCF8294
BCCB3720
BCBX2231

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anne Bergeron et al.
American journal of respiratory and critical care medicine, 191(11), 1242-1249 (2015-04-04)
Systemic steroids are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT) despite their poor efficacy and disabling side effects. To evaluate the effectiveness and tolerance of budesonide/formoterol as an alternative treatment for BOS
Sissie Wong et al.
Respiratory research, 10, 72-72 (2009-08-05)
There is currently a vast amount of evidence in the literature suggesting that matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in the pathogenesis of inflammatory airways diseases, such as asthma and COPD. Despite this, the majority
James Fingleton et al.
The Journal of allergy and clinical immunology, 136(3), 601-609 (2015-03-10)
Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and
Koremu K Meja et al.
American journal of respiratory cell and molecular biology, 39(3), 312-323 (2008-04-19)
Oxidative stress as a result of cigarette smoking is an important etiologic factor in the pathogenesis of chronic obstructive pulmonary disease (COPD), a chronic steroid-insensitive inflammatory disease of the airways. Histone deacetylase-2 (HDAC2), a critical component of the corticosteroid anti-inflammatory
Maciej Kupczyk et al.
Thorax, 68(7), 611-618 (2013-04-09)
Objective measures are required that may be used as a proxy for exacerbations in asthma. The aim was to determine the sensitivity and specificity of electronic diary data to detect severe exacerbations (SEs) of asthma. A secondary aim was to
View All Related Papers

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service